X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Idefirix (imlifidase) specifically targets and cleaves all classes of immunoglobulin G (IgG) antibodies. which is investigated for the treatment of highly sensitized kidney transplant patients.
Lead Product(s): Imlifidase
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 14, 2023
Details:
Idefirix (Imlifidase), IgG degrader enzyme in combination with Immunoglobulin antibodies. It is being evaluating in the Phase II clinical trial studies for the treatment of Guillain-Barre Syndrome.
Lead Product(s): Imlifidase,Immunoglobulin
Therapeutic Area: Rare Diseases and Disorders Product Name: Idefirix
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 07, 2023
Details:
Idefirix (imlifidase) specifically targets and cleaves all classes of immunoglobulin G (IgG) antibodies. which is investigated for the treatment of highly sensitized kidney transplant patients.
Lead Product(s): Imlifidase
Therapeutic Area: Immunology Product Name: Idefirix
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 11, 2023
Details:
HNSA-5487 is a next-generation IgG-cleaving enzyme, which is investigated for the treatment of IgG-driven autoimmune disease and experience flares, transplantation where repeat dosing would be beneficial, gene therapy and oncology.
Lead Product(s): HNSA-5487
Therapeutic Area: Immunology Product Name: HNSA-5487
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 09, 2023
Details:
Idefirix (imlifidase) specifically targets and cleaves all classes of immunoglobulin G (IgG) antibodies. which is investigated in phase 2 study in anti-neutrophil cytoplasmic antibody ("ANCA")-associated vasculitis.
Lead Product(s): Imlifidase
Therapeutic Area: Immunology Product Name: Idefirix
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 19, 2023
Details:
Idefirix (imlifidase) specifically targets and cleaves all classes of immunoglobulin G (IgG) antibodies. Idefirix® is conditionally authorized by the European Commission (EC) for the desensitization treatment of highly sensitized adult kidney transplant patients.
Lead Product(s): Imlifidase
Therapeutic Area: Immunology Product Name: Idefirix
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2023
Details:
Idefirix® (imlifidase) specifically targets and cleaves all classes of immunoglobulin G (IgG) antibodies for the treatment of anti-glomerular basement membrane (anti-GBM) disease.
Lead Product(s): Imlifidase,Cyclophosphamide
Therapeutic Area: Immunology Product Name: Idefirix
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 30, 2023
Details:
Idefirix (Imlifidase), an enzyme derived from bacterium streptococcus pyogenes, specifically target and cleave all classes of IgG antibodies. Imlifidase is a promising new strategy for desensitization of transplant patients with donor-specific anti-HLA antibodies.
Lead Product(s): Imlifidase
Therapeutic Area: Immunology Product Name: Idefirix
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 02, 2023
Details:
Idefirix® having Imlifidase, company’s first-in-class treatment, for the desensitization of highly sensitized adult patients prior to kidney transplant from a deceased donor.
Lead Product(s): Imlifidase
Therapeutic Area: Immunology Product Name: Idefirix
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 08, 2022
Details:
SRP-9001 (delandistrogene moxeparvovec), is an investigational gene transfer therapy intended to deliver its micro-dystrophin-encoding gene to muscle tissue for the targeted production of the micro-dystrophin protein.
Lead Product(s): Delandistrogene Moxeparvovec,Imlifidase
Therapeutic Area: Genetic Disease Product Name: SRP-9001
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Sarepta Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 02, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
